Roche Signals it is Too Soon to Know if AI Improves Trial Success Rates

Dow Jones09-29 20:22

1222 GMT - Roche Holding's research and early development is becoming more productive thanks to the integration of AI into its workflows, but it is too soon to know if the technology improves a drug candidate's chances in a clinical trial, J.P. Morgan analysts say in a research note. The Swiss drugmaker said it is using AI to speed up the process of discovering new medicines, and ultimately aims to improve the quality of those that it moves to the development phase. "While they are making significant progress enhancing the research process, whether this will lead to enhanced probability of success will only become clear as the molecules go through clinical testing over the coming 3-5 years," the analysts say. Shares fall 1.4%.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment